Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
MTPC Licenses VMAT2 Inhibitor from Neurocrine Biosciences
Mitsubishi Tanabe Pharma Corporation (MTPC) said on April 1 that it entered into a license agreement with Neurocrine Biosciences of the US on March 31 for exclusive rights to develop and commercialize the vesicular monoamine transporter type 2 (VMAT2) inhibitor…
To read the full story
Related Article
- Mitsubishi Tanabe, Janssen to Copromote Dyskinesia Med in Japan
December 6, 2021
- Mitsubishi Tanabe Files Tardive Dyskinesia Drug in Japan
April 23, 2021
BUSINESS
- Lilly’s Omvoh 200 mg SC Wins Japan Nod for UC Maintenance Use
April 17, 2026
- Sobi Japan Shoots for 8 to 9-Fold Growth by 2030 on Five Approvals
April 17, 2026
- Sanofi Japan Chief Iwaya to Step Down at June End, Leave EFPIA Role
April 16, 2026
- Suntory to Acquire Daiichi Sankyo’s OTC Business for 246.5 Billion Yen
April 16, 2026
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…